Gadeta, a clinical-stage company developing gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for cancer patients, has announced the dosing of the first patient with GDT-002 (formerly labelled TEG002), a potential first-in-class cellular immunotherapy for the treatment of cancer.
The multicentre Phase I/II study in collaboration with the Dana-Farber Cancer Institute, Mass General Brigham Cancer Care and Beth Israel Deaconess Medical Center, is evaluating safety, tolerability and preliminary efficacy of GDT-002 for the treatment of multiple myeloma (MM).
“The initiation of our Phase I/II trial of GDT-002 and the dosing of our first patient are a transformational milestone for Gadeta in its mission to provide novel treatments to patients with cancer, including MM,” said Dr Marco Londei, Chief Executive Officer of Gadeta. “Despite the successes with CAR-T and related therapies, patients often develop resistance to currently approved treatments. We believe GDT-002 offers potential as a possible new treatment option for patients with multiple myeloma and potentially other liquid and solid cancers.”
GDT-002 is a cell therapy product utilising specific γδ TCR for the treatment of a wide range of cancers. The target recognised by GDT-002 is unregulated in a wide range of liquid and solid tumours, presenting great therapeutic potential. Preclinical studies have shown that GDT-002 selectively kills primary naïve and relapsed/refractory MM cells and has an activity comparable, in MM animal models, to that of BCMA CAR-T. Importantly, a broad spectrum of liquid and solid tumours is recognised by GDT-002.
Gadeta is developing a pipeline of cell therapies, utilising tumour specific γδ TCRs. Gadeta aims to bring its novel pipeline of selected, γδ TCR-based products to the clinic, with a focus on solid tumours.
